Gain Therapeutics, Inc. (GANX) bonds
GANXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 3/30
$1.18+0.24 (+25.51%)
Close on Nov 17, 2026Market cap $51.50MP/E –Yield –
Debt
Borrowings on the balance sheet, Jun 30, 2026
Total debt
$343.69K
$123.63K due within a year
Net debt
-$12.74M
After $13.08M of cash
Implied interest rate
–
FY2025 interest ÷ average debt
Interest coverage
–
FY2025 operating income ÷ interest
Total debt by fiscal year
Long-term plus current debt, USD
When the debt comes due
Principal repayments of long-term debt by fiscal year, as scheduled at Dec 31, 2023
From the debt maturity table in the annual report (filing). “Later” is everything due after year five.
Notes and loans outstanding
As tagged in Gain Therapeutics's 10-Q for the period ended Aug 31, 2020
| Issue | Coupon | Amount issued |
|---|---|---|
| August 2020 CHF loan | 0.00% | CHF 638.00K |
Companies tag their debt differently: some list every note, others group notes by issuance year or by type, so the list may not add up to total debt. Notes that matured before today are hidden. Source: 10-Q.
See a number that looks wrong?